MetaCap

Larimar Therapeutics (LRMR) vs PepGen (PEPG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Larimar Therapeutics (LRMR) has outperformed PepGen (PEPG) over the past year, losing 11.8% versus a loss of 32.0%. PepGen is the larger company by market cap ($356.3 million vs $328.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LRMR-11.80%PEPG-32.01%
+74%-4%-83%
Nov 21, 20251 yearNov 20, 2026
LRMR-8.99%PEPG-70.67%
+289%+89%-110%
May 2, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LRMR versus PEPG key metrics
MetricLRMRPEPG
Share price$3.14$3.78
Market cap$328.55M$356.31M
1-day change-2.48%-3.82%
YTD return-17.59%-41.94%
1-year return-11.80%-32.01%
5-year return-68.97%—
EPS (TTM)$-1.67$-0.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-165.67M$-89.66M
52-week high$6.42$7.80
52-week low$1.92$1.31
Distance from 52-week high-51.09%-51.54%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+352.23%+263.76%
Average volume1.38M3.26M
Shares outstanding104.63M94.26M
Employees7153
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LRMR has outperformed PEPG by 20.2 percentage points over the past year.

About Larimar Therapeutics

LRMR stock →

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees

About PepGen

PEPG stock →

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.

Health Care · Biotechnology: Pharmaceutical Preparations · 53 employees

LRMR vs PEPG FAQ

Which is bigger, Larimar Therapeutics or PepGen?

PepGen (PEPG) is larger, with a market capitalization of $356.31M compared with $328.55M for Larimar Therapeutics (LRMR).

Which stock has performed better over the past year, LRMR or PEPG?

LRMR returned -11.80% over the past 12 months, compared with -32.01% for PEPG (price return, excluding dividends). Past performance does not predict future results.

Are Larimar Therapeutics and PepGen in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons